Snapshot from Sep 19, 2026 at 07:00 UTC. For live data and tracking: View Live
Business funding round

Thyme Care Series E Funding

Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026

Sentiment
70
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The funding round signals strong investor confidence in value-based oncology care, potentially boosting Thyme Care's growth and market position. It may also positively influence the broader healthcare services sector, particularly companies focused on cancer care management and cost reduction.

Healthcare Health Insurance Biotechnology

Thyme Care, a Nashville-based oncology care company, announced a Series E financing round of over $125 million, led by Morgan Health, with participation from strategic investors including Humana, CVS Health Ventures, and several venture capital firms. The round values Thyme Care at more than $2 billion. The company also established Thyme Companies, a new parent entity, to build a portfolio of independent oncology businesses addressing barriers such as biosimilar adoption and clinical trial accrual. Thyme Care manages over $7 billion in oncology spend and serves 10.5 million people across all 50 states. The company is profitable and generates positive free cash flow. Leadership changes include co-founder Robin Shah becoming Executive Chairman of Thyme Companies, while Brad Diephuis continues as CEO of Thyme Care.

priv
Thyme Care is the primary entity, raising over $125 million at a $2 billion valuation. The funding will accelerate its growth and support the launch of Thyme Companies, enhancing its market position in oncology care.
Importance 100.0 Sentiment 90.0
priv
Thyme Companies is a newly formed parent entity established to develop new oncology businesses. It will be led by Robin Shah and is expected to launch its first business later this year.
Importance 80.0 Sentiment 85.0
priv
Morgan Health led the Series E round, demonstrating its commitment to value-based care. This investment strengthens its portfolio in healthcare innovation.
Importance 70.0 Sentiment 80.0
per
Robin Shah, co-founder, transitions to Executive Chairman of Thyme Companies, leading new business development. This move leverages his strategic vision to expand the company's impact.
Importance 60.0 Sentiment 75.0
stock
Humana participated as a strategic investor, aligning with its focus on improving cancer care and reducing costs for its members.
Importance 50.0 Sentiment 70.0
stock
CVS Health Ventures invested in Thyme Care, supporting its expansion into oncology care management and potential synergies with its healthcare services.
Importance 50.0 Sentiment 70.0
per
King Green, co-founder, continues as President and Chief Medical Officer of Thyme Care, ensuring clinical leadership and continuity.
Importance 50.0 Sentiment 70.0
per
Brad Diephuis remains CEO of Thyme Care, leading its operations and growth. His leadership is crucial for executing the company's expansion plans.
Importance 50.0 Sentiment 70.0
per
Dan Mendelson, CEO of Morgan Health, led the investment and expressed confidence in Thyme Care's ability to deliver value, reinforcing the strategic partnership.
Importance 40.0 Sentiment 70.0
priv
Kevin P. Ryan participated as an institutional investor, gaining exposure to the growing oncology care market.
Importance 30.0 Sentiment 65.0
priv
HealthQuest Capital invested in Thyme Care, adding to its portfolio of healthcare companies.
Importance 30.0 Sentiment 65.0
priv
Foresite Capital participated in the round, supporting Thyme Care's data-driven approach to oncology.
Importance 30.0 Sentiment 65.0
priv
Concord Health Partners invested, reflecting confidence in Thyme Care's business model.
Importance 30.0 Sentiment 65.0
priv
Frist Cressey Ventures participated, aligning with its healthcare investment focus.
Importance 30.0 Sentiment 65.0
priv
Town Hall Ventures invested, supporting Thyme Care's mission to improve cancer care access.
Importance 30.0 Sentiment 65.0
+ 1 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.